The opioid oxymorphone (Numorphan, Endo) delivered in a new extended-release (ER) formulation significantly improves standard measures of pain and physical function in osteoarthritis (OA) patients, researchers reported at the American College of Rheumatology 67th Annual Scientific Meeting.